Brian W. Metcalf is Chief Drug Discovery Scientist at INCYTE CORP (INCY). They have made 5 open-market trades across 1 company since 2006, most recently 2011-04-11.
CIK 0001234564
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $30K since 2006, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| INCY | 116,504 | $13.2M |
Shares reported on the most recent Form 4, priced at the 2011-04-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INCY | SELL | 2011-04-11 | 2011-04-13 | $17.41 | $1.7M | -26.4% | -3.0% | -3.0% |
| INCY | SELL | 2011-03-16 | 2011-03-18 | $14.26 | $3.0M | -26.4% | -3.0% | -3.0% |
| INCY | SELL | 2011-02-17 | 2011-02-22 | $14.35 | $718K | -26.4% | -3.0% | -3.0% |
| INCY | BUY | 2008-11-21 | 2008-11-24 | $2.19 | $11K | -26.4% | -3.0% | -3.0% |
| INCY | BUY | 2006-04-17 | 2007-02-13 | $3.88 | $19K | -26.4% | -3.0% | -3.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.